A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

A new ultrasound-based technique developed by researchers at Duke University uses microbubbles to deliver cancer drugs directly into tumour cells, showing promise for highly targeted treatments that cause minimal damage to healthy tissue.

ELRIG has announced the keynote speakers for its 2026 Advances in Cell-based Screening conference in Gothenburg, where scientists will gather to explore how human-first models, advanced cell biology and AI are changing the future of drug discovery.

A new RNA-based therapy developed at Columbia University could help the heart repair itself after a heart attack without invasive surgery.

Researchers at Osaka Metropolitan University have developed a novel drug delivery system that improves the solubility of the anticancer drug paclitaxel.

Scientists at the University of Cambridge have developed a light-powered method to modify complex drug molecules without toxic chemicals, enabling faster, cleaner and more efficient drug development.

A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.